CA2869547A1 - Asymmetric syntheses for spiro-oxindole compounds useful as therapeutic agents - Google Patents
Asymmetric syntheses for spiro-oxindole compounds useful as therapeutic agents Download PDFInfo
- Publication number
- CA2869547A1 CA2869547A1 CA2869547A CA2869547A CA2869547A1 CA 2869547 A1 CA2869547 A1 CA 2869547A1 CA 2869547 A CA2869547 A CA 2869547A CA 2869547 A CA2869547 A CA 2869547A CA 2869547 A1 CA2869547 A1 CA 2869547A1
- Authority
- CA
- Canada
- Prior art keywords
- formula
- compound
- enantiomers
- heteroaryl
- aryl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/20—Spiro-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/32—Oxygen atoms
- C07D209/34—Oxygen atoms in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Indole Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261623336P | 2012-04-12 | 2012-04-12 | |
| US61/623,336 | 2012-04-12 | ||
| PCT/US2013/030219 WO2013154712A1 (en) | 2012-04-12 | 2013-03-11 | Asymmetric syntheses for spiro-oxindole compounds useful as therapeutic agents |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2869547A1 true CA2869547A1 (en) | 2013-10-17 |
Family
ID=47902379
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2869547A Pending CA2869547A1 (en) | 2012-04-12 | 2013-03-11 | Asymmetric syntheses for spiro-oxindole compounds useful as therapeutic agents |
Country Status (14)
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HRP20150882T1 (hr) | 2008-10-17 | 2015-09-25 | Xenon Pharmaceuticals Inc. | Spirooksindolski spojevi i njihova upotreba kao terapijska sredstva |
| AR077252A1 (es) | 2009-06-29 | 2011-08-10 | Xenon Pharmaceuticals Inc | Enantiomeros de compuestos de espirooxindol y sus usos como agentes terapeuticos |
| PE20170202A1 (es) | 2009-10-14 | 2017-03-24 | Xenon Pharmaceuticals Inc | Metodos sinteticos para compuestos espiro-oxoindol |
| RU2596488C2 (ru) | 2010-02-26 | 2016-09-10 | Ксенон Фармасьютикалз Инк. | Фармацевтические композиции спиро-оксиндольного соединения для местного введения и их применение в качестве терапевтических агентов |
| KR20150002794A (ko) | 2012-04-12 | 2015-01-07 | 제논 파마슈티칼스 인크. | 치료제로서 유용한 스파이로-옥시인돌 화합물을 위한 비대칭적 합성 |
| WO2016109795A1 (en) | 2014-12-31 | 2016-07-07 | Concert Pharmaceuticals, Inc. | Deuterated funapide and difluorofunapide |
| AR103636A1 (es) | 2015-02-05 | 2017-05-24 | Teva Pharmaceuticals Int Gmbh | Métodos de tratamiento de neuralgia postherpética con una formulación tópica de un compuesto de espiro-oxindol |
| WO2017180248A1 (en) * | 2016-04-15 | 2017-10-19 | William Marsh Rice University | Enantioenriched viridicatumtoxin b analogs |
| EP3468545B1 (en) | 2016-06-08 | 2026-08-05 | President and Fellows of Harvard College | Methods and compositions for reducing tactile dysfunction and anxiety associated with autism spectrum disorder, rett syndrome, and fragile x syndrome |
| WO2017218920A1 (en) | 2016-06-16 | 2017-12-21 | Teva Pharmaceuticals International Gmbh | Asymmetric synthesis of funapide |
| CN109311905A (zh) * | 2016-06-16 | 2019-02-05 | 泽农医药公司 | 螺-吲哚酮化合物的固态形式 |
| CN108395438A (zh) * | 2018-04-03 | 2018-08-14 | 陕西科技大学 | 一类具有抗菌活性的靛红母核螺环化合物及其合成方法 |
| WO2019226808A1 (en) | 2018-05-22 | 2019-11-28 | President And Fellows Of Harvard College | Compositions and methods for reducing tactile dysfunction, anxiety, and social impairment |
| EP3801512A4 (en) | 2018-05-29 | 2022-01-19 | President and Fellows of Harvard College | COMPOSITIONS AND METHODS TO REDUCE TACTILE DYSFUNCTION, ANXIETY AND SOCIAL DISABILITIES |
| US12077512B2 (en) | 2019-03-25 | 2024-09-03 | President And Fellows Of Harvard College | Compositions and methods for reducing tactile dysfunction, anxiety, and social impairment |
| CN116057045B (zh) | 2020-06-05 | 2026-06-09 | 金耐特生物制药公司 | 成纤维细胞生长因子受体激酶抑制剂 |
| US12552808B2 (en) | 2020-09-03 | 2026-02-17 | Amgen Inc. | Diol desymmetrization by nucleophilic aromatic substitution |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3723459A (en) | 1971-04-23 | 1973-03-27 | Mc Neil Labor Inc | 2-oxospiro (indoline -3,4{40 -thiochroman) derivatives |
| JPS6130554A (ja) | 1984-07-23 | 1986-02-12 | Ono Pharmaceut Co Ltd | プロスタグランジン類似化合物のある特定の立体配置を有する異性体及びそれらを有効成分として含有する治療剤 |
| DE3608088C2 (de) | 1986-03-07 | 1995-11-16 | Schering Ag | Pharmazeutische Präparate, enthaltend Cyclodextrinclathrate von Carbacyclinderivaten |
| JP2716986B2 (ja) | 1987-07-17 | 1998-02-18 | シエーリング アクチエンゲゼルシヤフト | 9‐ハロゲン‐(z)‐プロスタグランジン誘導体、その製法及び薬剤としてのその使用 |
| US5314685A (en) | 1992-05-11 | 1994-05-24 | Agouron Pharmaceuticals, Inc. | Anhydrous formulations for administering lipophilic agents |
| NO317155B1 (no) | 1997-02-04 | 2004-08-30 | Ono Pharmaceutical Co | <omega>-cykloalkyl-prostagladin-E<N>2</N>-derivater |
| ATE237587T1 (de) | 1997-02-10 | 2003-05-15 | Ono Pharmaceutical Co | 11,15-o-dialkylprostaglandin-e-derivate, verfahren zu ihrer herstellung und arzneimittel, die diese als aktiven inhaltsstoff enthalten |
| WO1999033794A1 (en) | 1997-12-25 | 1999-07-08 | Ono Pharmaceutical Co., Ltd. | φ-CYCLOALKYL-PROSTAGLANDIN E2 DERIVATIVES |
| JP4087938B2 (ja) | 1998-02-04 | 2008-05-21 | 高砂香料工業株式会社 | ヒノキチオ−ル類の分岐サイクロデキストリン包接化合物からなる抗菌剤およびそれを含有する組成物 |
| US6235780B1 (en) | 1998-07-21 | 2001-05-22 | Ono Pharmaceutical Co., Ltd. | ω-cycloalkyl-prostaglandin E1 derivatives |
| SE9900100D0 (sv) | 1999-01-15 | 1999-01-15 | Astra Ab | New compounds |
| JPWO2005035498A1 (ja) | 2003-10-08 | 2006-12-21 | 住友製薬株式会社 | 含窒素二環性化合物の摂食調節剤としての用途 |
| JP2007536283A (ja) | 2004-05-05 | 2007-12-13 | ユニバイオスクリーン エス.アー. | ナフタルイミド誘導体、それらの製造方法、およびそれらの医薬組成物 |
| MY144968A (en) | 2005-04-11 | 2011-11-30 | Xenon Pharmaceuticals Inc | Spiro-oxindole compounds and their uses as therapeutic agents |
| AR053710A1 (es) | 2005-04-11 | 2007-05-16 | Xenon Pharmaceuticals Inc | Compuestos espiroheterociclicos y sus usos como agentes terapeuticos |
| SI1924264T1 (sl) | 2005-09-01 | 2013-12-31 | F. Hoffmann-La Roche Ag | Diaminopirimidini kot modulatorji p2x3 in p2x2/3 |
| WO2007081895A2 (en) * | 2006-01-09 | 2007-07-19 | Merck & Co., Inc. | Preparation of substituted 2-hydroxygibba-1(10a), 2, 4, 4b-tetraen-6-ones |
| WO2008046049A1 (en) | 2006-10-12 | 2008-04-17 | Xenon Pharmaceuticals Inc. | Spiro (furo [3, 2-c] pyridine-3-3 ' -indol) -2' (1'h)-one derivatives and related compounds for the treatment of sodium-channel mediated diseases, such as pain |
| WO2008046087A2 (en) | 2006-10-12 | 2008-04-17 | Xenon Pharmaceuticals Inc. | Spiro compounds and their uses as therapeutic agents |
| EP2073806B1 (en) | 2006-10-12 | 2012-02-15 | Xenon Pharmaceuticals Inc. | Use of spiro-oxindole compounds as therapeutic agents |
| BRPI0719166A2 (pt) | 2006-10-12 | 2014-06-03 | Xenon Pharmaceuticals Inc | Derivados de espiro-oxindol tricíclicos e seus usos como agentes terapêuticos |
| GB0704846D0 (en) | 2007-03-13 | 2007-04-18 | Futura Medical Dev Ltd | Topical pharmaceutical formulation |
| WO2010045197A1 (en) | 2008-10-17 | 2010-04-22 | Xenon Pharmaceuticals, Inc. | Spiro-oxindole compounds and their use as therapeutic agents |
| HRP20150882T1 (hr) | 2008-10-17 | 2015-09-25 | Xenon Pharmaceuticals Inc. | Spirooksindolski spojevi i njihova upotreba kao terapijska sredstva |
| US20110269788A1 (en) | 2008-12-29 | 2011-11-03 | Xenon Pharmaceuticals Inc. | Spiro-oxindole-derivatives as sodium channel blockers |
| US8295257B2 (en) | 2009-03-13 | 2012-10-23 | Telcordia Technologies, Inc. | Scalable disruptive-resistant communication method |
| WO2010132352A2 (en) * | 2009-05-11 | 2010-11-18 | Xenon Pharmaceuticals Inc. | Spiro compounds and their use as therapeutic agents |
| AR077252A1 (es) | 2009-06-29 | 2011-08-10 | Xenon Pharmaceuticals Inc | Enantiomeros de compuestos de espirooxindol y sus usos como agentes terapeuticos |
| PE20170202A1 (es) | 2009-10-14 | 2017-03-24 | Xenon Pharmaceuticals Inc | Metodos sinteticos para compuestos espiro-oxoindol |
| US20110086899A1 (en) | 2009-10-14 | 2011-04-14 | Xenon Pharmaceuticals Inc. | Pharmaceutical compositions for oral administration |
| RU2596488C2 (ru) | 2010-02-26 | 2016-09-10 | Ксенон Фармасьютикалз Инк. | Фармацевтические композиции спиро-оксиндольного соединения для местного введения и их применение в качестве терапевтических агентов |
| KR20150002794A (ko) | 2012-04-12 | 2015-01-07 | 제논 파마슈티칼스 인크. | 치료제로서 유용한 스파이로-옥시인돌 화합물을 위한 비대칭적 합성 |
-
2013
- 2013-03-11 KR KR1020147031580A patent/KR20150002794A/ko not_active Withdrawn
- 2013-03-11 EP EP13710961.7A patent/EP2838902B1/en active Active
- 2013-03-11 MX MX2014012266A patent/MX2014012266A/es unknown
- 2013-03-11 JP JP2015505723A patent/JP6195609B2/ja not_active Expired - Fee Related
- 2013-03-11 CA CA2869547A patent/CA2869547A1/en active Pending
- 2013-03-11 WO PCT/US2013/030219 patent/WO2013154712A1/en not_active Ceased
- 2013-03-11 US US13/794,147 patent/US9487535B2/en active Active
- 2013-03-11 EA EA201491854A patent/EA201491854A1/ru unknown
- 2013-03-11 HK HK15105599.7A patent/HK1205114A1/xx unknown
- 2013-03-11 CN CN201380030552.0A patent/CN104350057A/zh active Pending
- 2013-03-11 ES ES13710961T patent/ES2714314T3/es active Active
- 2013-03-11 AU AU2013246485A patent/AU2013246485A1/en not_active Abandoned
- 2013-03-11 CN CN201610207838.7A patent/CN105753877A/zh active Pending
- 2013-03-11 HK HK15105598.8A patent/HK1205113A1/xx unknown
-
2014
- 2014-10-06 IL IL235006A patent/IL235006A0/en unknown
- 2014-10-09 ZA ZA2014/07334A patent/ZA201407334B/en unknown
-
2015
- 2015-06-12 HK HK16114577.4A patent/HK1226389A1/zh unknown
-
2016
- 2016-09-14 US US15/265,549 patent/US20170066777A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| KR20150002794A (ko) | 2015-01-07 |
| IL235006A0 (en) | 2014-12-31 |
| WO2013154712A1 (en) | 2013-10-17 |
| EP2838902A1 (en) | 2015-02-25 |
| US20130274483A1 (en) | 2013-10-17 |
| CN104350057A (zh) | 2015-02-11 |
| US9487535B2 (en) | 2016-11-08 |
| ZA201407334B (en) | 2017-05-31 |
| HK1226389A1 (zh) | 2017-09-29 |
| JP2015516389A (ja) | 2015-06-11 |
| EA201491854A1 (ru) | 2015-03-31 |
| US20170066777A1 (en) | 2017-03-09 |
| AU2013246485A1 (en) | 2014-10-16 |
| ES2714314T3 (es) | 2019-05-28 |
| CN105753877A (zh) | 2016-07-13 |
| HK1205114A1 (en) | 2015-12-11 |
| JP6195609B2 (ja) | 2017-09-13 |
| MX2014012266A (es) | 2014-12-05 |
| EP2838902B1 (en) | 2018-12-05 |
| HK1205113A1 (en) | 2015-12-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2838902B1 (en) | Asymmetric syntheses for spiro-oxindole compounds useful as therapeutic agents | |
| JP6799037B2 (ja) | 化学的方法 | |
| WO2017100546A1 (en) | Methods for preparation of quinazoline derivatives | |
| HU222724B1 (hu) | Eljárás 3-amino-2-fenil-piperidin elżállítására | |
| JPH0544948B2 (cg-RX-API-DMAC10.html) | ||
| JP2011519343A (ja) | Trpv3モジュレーターとしてのクロマン誘導体 | |
| JP2011519343A5 (cg-RX-API-DMAC10.html) | ||
| WO2025096895A1 (en) | Carbamothioate, and carbamodithioate derivatives of mdma, mda or its optically active ( r)- or ( s)-mdma and mda isomers | |
| AU2023395940A1 (en) | Prodrugs of dimethyltryptamine and derivatives thereof | |
| JP2010532357A (ja) | 1,2−置換3,4−ジオキソ−1−シクロブテン化合物における制御された結晶サイズのための方法 | |
| CA2016625A1 (en) | 3,4-dehydropiperidine derivatives having psychotropic activity | |
| CN101484445A (zh) | 吡咯烷取代的黄酮的对映选择性合成 | |
| Chandrasekhar et al. | Practical and highly stereoselective approaches to the total synthesis of (−)-codonopsinine | |
| DE69631521T2 (de) | Propenonderivate | |
| EA007714B1 (ru) | Новые соединения изохинолина, способ их получения и фармацевтические композиции, содержащие их | |
| RU2032663C1 (ru) | 4-(3-этил-(3-(пропилсульфинил) -пропил)-амино)-2-гидроксипропокси) -бензонитрил в виде стереоизомеров или их фармацевтически приемлемые соли и способ их получения | |
| AU6296896A (en) | Novel heterocyclic compounds for the treatment of pain and use thereof | |
| CN115836059B (zh) | 异吲哚啉酮衍生物的制备方法、该方法所使用的新型中间体及其制备方法 | |
| CA2017911A1 (en) | 4,5,6,11-tetrahydrobenzo [6,7] -cycloocta [1,2-b] thiophen-6,11-imines and 6,11-dihydrobenzo [6,7] -cycloocta [1,2-b] thiophen-6,11 imines | |
| JPH08208595A (ja) | スルホンアミド化合物、その製造法および剤 | |
| KR20010013435A (ko) | 5-나프탈렌-1-일-1,3-디옥산 유도체, 제조 및 치료에의 이용 | |
| Zhang et al. | Supplementary Information for Nickel-Catalyzed Deaminative Sonogashira Coupling of Alkylpyridinium Salts Enabled by a New NN2 Pincer Ligand | |
| DE3801479A1 (de) | Pilocarpinderivate |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20190308 |
|
| N11 | Application terminated |
Free format text: ST27 STATUS EVENT CODE: T-6-6-N10-N11-N106 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION NOT REINSTATED BY DEADLINE Effective date: 20240911 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 12TH ANNIV.) - STANDARD Year of fee payment: 12 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: N-6-6-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20241220 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: N-6-6-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20260106 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: T-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20260423 |